SEC For	m 4																	
	FORM	4	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549												OMB APPROVAL			
Section 16. Form 4 or Form 5 obligations may continue. See					NT OF CHANGES IN BENEFICIAL OWNER ed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940								Ρ	Estima	Number: ated ave per resp	rage burden	3235-0287 0.5	
1. Name and Address of Reporting Person [*] Roshwalb Gur					2. Issuer Name and Ticker or Trading Symbol <u>Akari Therapeutics Plc</u> [AKTX]								all applicab			10% Ow	ner	
(Last) (First) (Middle) C/O AKARI THERAPEUTICS PLC 24 WEST 40TH STREET, 8TH FLOOR					3. Date of Earliest Transaction (Month/Day/Year) 09/21/2015							X	X Officer (give title Other (specify below) below) Chief Executive Officer					
(Street) NEW YORK NY 10018					4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Indiv X	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City) (State) (Zip)																		
			Table I - Non-	Deriva	ative	Securitie	s Ao	quired, D	isposed	of, or Be	enefic	ially O	wned					
Date				action 2A. Deemed Execution Day/Year) if any (Month/Day/Y		n Date	Code (Ins	ion Dispose			and 5) Securities Beneficially Following		Form:		Direct I Indirect E tr. 4) C	7. Nature of Indirect Beneficial Ownership		
								Code \	/ Amoun	t (A) (D)	or P	rice	Reported Transactior (Instr. 3 and	(s) 4)			Instr. 4)	
			Table II - D (e					uired, Dis s, options					ned				<u> </u>	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exerc Expiration D (Month/Day/	ate	nd 7. Title and A Securities U Derivative S (Instr. 3 and		lying	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amour Numbe Shares	er of		Transaction(s) (Instr. 4)				
Options to Purchase Ordinary Shares	\$0.3221	09/21/2015		A		32,543,700		(1)	09/21/2025	Ordinary Shares	32,54	43,700	\$0	32,543	,700	D		

Explanation of Responses:

1. The option vests as to 12.5% of the shares on March 18, 2016 and as to an additional 12.5% of the shares on each six month anniversary thereafter over a period of four years from September 18, 2015, provided that Gur Roshwalb remains employed by the Company on the vesting date, and provided further that a minimum of 25% will vest regardless of his employment status. These options will expire 10 years from issuance.

 /s/ Dov Elefant, as attorney-infact
 09/22/2015

 ** Signature of Reporting Person
 Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 \ast If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.